Feasibility of Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer

Not Applicable

Completed

• Conditions: Muscle Invasive Bladder Cancer; Cancer - Bladder

• Registration Number: ACTRN12610000711011
• Lead Sponsor: Trans Tasman Radiation Oncology Group (TROG)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-08-26
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Aged 18 years or older 2. Has provided written Informed Consent for participation in this trial 3. Histologically confirmed muscle invasive bladder cancer. 4. Transitional cell, squamous cell, adenocarcinoma or mixed histology. Stage T2-4 N0 M0. 5. An Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. 6. Life expectancy greater than 6 months. 7. Considered suitable for radical radiotherapy.
8. Participants capable of childbearing are using adequate contraception. 9. Radiotherapy must be able to be commenced within 12 weeks of surgery. 10. Available for follow up.

Exclusion Criteria

1. Women who are pregnant or lactating. 2. Previous pelvic radiotherapy 3. Previous cystectomy 4. A small contracted bladder 5. Unilateral or bilateral hip replacement 6. Small cell histology 7.Clinical or radiological evidence of nodal or distant metastases 8. Presence of indwelling urinary catheter

Study & Design

• Study Type: Interventional
• Study Design: Not specified